Temitayo Oluwatomisin Ajayi

Temitayo Oluwatomisin Ajayi

Auto-generated profile, based on publicly available information

Temitayo Oluwatomisin Ajayi

Department of Medical Laboratory Science, School of Public and Allied Health, Babcock University, Ilishan-Remo 121109, Ogun State, Nigeria

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 December 2024 in Avicenna Journal of Clinical Microbiology and Infection
Verified
Journal Article
Open access
PDF file
SESeyi Samson Enitan
Seyi Samson Enitan
RARichard Yomi Akele
Richard Yomi Akele
AOAdesuyi Ayodeji Omoare
Adesuyi Ayodeji Omoare
BDBanenat Dogonyaro
Banenat Dogonyaro
MIMichael Unata Iduh
Michael Unata Iduh
TATemitayo Oluwatomisin Ajayi
Temitayo Oluwatomisin Ajayi
Mpox, declared a Public Health Emergency of International Concern by the World Health Organization (WHO), poses a growing global threat. The resurgence, driven by the highly transmissible and severe clade Ib strain from the Democratic Republic of the Congo, raises concerns about a potential pandemic. This narrative review aims to identify actionable strategies to mitigate the current Mpox outbreak by leveraging lessons from past health crises, particularly COVID-19, and to highlight future research priorities essential for global preparedness. A comprehensive literature review from 2018 to 2024 was conducted using Google Scholar, Scopus, and PubMed databases, focusing on Mpox transmission, vaccine efficacy, antiviral treatments, and public health responses. Our findings revealed that the resurgence of Mpox is fueled by viral evolution, ecological changes, and inadequate surveillance, exacerbated by inequitable healthcare access and insufficient public health infrastructure. While existing vaccines, such as Jynneos and ACAM2000, offer protection, their long-term efficacy and safety across diverse populations require further study. Antiviral treatments, including tecovirimat and brincidofovir, show promise but lack optimized care protocols and face challenges such as emerging resistance. Lessons from the COVID-19 response underscore the importance of enhancing global surveillance systems, strengthening healthcare infrastructure, ensuring equitable vaccine distribution, and fostering community engagement. Effective Mpox management also requires standardized treatment guidelines and the integration of genomic monitoring to track viral evolution and drug resistance. Urgent international collaboration is needed to avert a potential Mpox pandemic. Priorities include advancing research on long-term vaccine efficacy, optimizing antiviral therapies, and improving care for severe cases. Actionable recommendations include robust policies, sustainable funding, and global collaboration to strengthen pandemic preparedness and mitigate Mpox’s impact.

20 August 2024 in Acta Elit Salutis
Verified
Journal Article
Open access
TATemitayo Oluwatomisin Ajayi
Temitayo Oluwatomisin Ajayi
OAOyebode Armstrong Terry Alli
Oyebode Armstrong Terry Alli
SESeyi Enitan
Seyi Enitan
MDMichael Olugbamila Dada
Michael Olugbamila Dada
EEEffiong Joseph Effiong
Effiong Joseph Effiong
Background: In Nigeria, where malaria is endemic, greater than 70% of febrile illnesses are treated presumptively as malaria, often without a laboratory evaluation for other possible causes of fever. Dengue virus infection presents a significant health challenge in tropical regions, often exhibiting clinical symptoms similar to malaria. In Ogun State, Nigeria, febrile patients are frequently presumed to have malaria, potentially overlooking concurrent or alternative infections like dengue. Accurate diagnosis is crucial for appropriate treatment and management. The aim of this study was to determine the prevalence of dengue virus antibodies and antigen among febrile patients attending a state hospital in Ogun State. Methodology: Blood samples from 120 consenting febrile patients suspected of malaria in Ogun state were evaluated for the presence of malaria parasites by microscopic examination of Giemsa-stained blood smears and also tested for the presence of anti-dengue immunoglobulin M (IgM) and immunoglobulin G (IgG), as well as anti-non-structural protein (NS1) using lateral flow chromatographic immunoassay in line with manufacturer’s instructions. The study lasted for three months (January- March, 2024). Data analysis was done using the Statistical Package for the Social Sciences (SPSS). A p value <0.05 was considered statistically significant. Results: The percentage occurrence of Dengue IgG Ab only, NS1 Ag, IgM Ab + NS1 Ag and IgM Ab + IgG Ab + NS1 Ag combined were: 4.2%, 0.8%, 3.3% and 6.7%, respectively. In all, 50% tested positive to malaria. A statistically significant association (p=0.026) was found between gender and preventive practice. Females exhibited higher proportions of good preventive practice 45.0% compared to males (20.8%). A significant association (p=0.014) was observed between age range and Dengue NS1 antigen status. Conclusion: These findings imply dengue fever should feature as a prominent differential diagnosis for febrile illnesses and screening for dengue virus should be part of routine tests amongst patients that presents with febrile illness. Given the prevalence of dengue virus infections, there is also a need for a dengue control programme and public education to prevent outbreaks and occurrence of severe dengue complications.